Abstract:BACKGROUND: Little is known about the maintenance of amenorrhea among transgender and gender-diverse individuals with uteri who are using long-term testosterone gender-affirming hormone therapy. Emerging data describe breakthrough bleeding among adolescents on long-term testosterone therapy and among adults who are seeking a gender-affirming hysterectomy. More studies are needed to better understand breakthrough bleeding patterns among transgender and gender-diverse individuals with uteri who are using testosterone, including the frequency, timing, and etiology of bleeding and how these patterns may differ between adults and younger populations.OBJECTIVE: The primary aim of this study was to characterize the incidence and patterns of breakthrough bleeding in a cohort of transgender and gender-diverse individuals who had been on testosterone for longer than 12 months and who had uteri in situ. Secondary aims included identifying the time to first bleed for those who experienced breakthrough bleeding and the risk factors associated with breakthrough bleeding while on testosterone therapy.STUDY DESIGN: This was an institutional review board-approved, single tertiary center, retrospective chart review of transgender and gender diverse individuals who had been on testosterone for at least 1 year. A primary survival analysis that evaluated the incidence of bleeding was combined with descriptive analyses and an evaluation of the factors associated with bleeding.RESULTS: Of the 279 patients included in the analysis, the median age of testosterone initiation was 22 years (interquartile range, 19-41), and the median follow-up time was 34 months (range, 12-278). The absolute proportion of individuals who ever experienced breakthrough bleeding on testosterone was 34% (n=96; 95% confidence interval, 29-40). Patients who experienced breakthrough bleeding initiated testosterone at a younger age (20.5 vs 22.0 years; P=.04), had lower mean serum testosterone levels (389.14 vs 512.7 ng/dL; P=.001), were more likely to have a mean testosterone level <320 ng/dL (52% vs 48%; P=.001), and had higher mean estradiol levels (62% vs 49%; P=.003). Survival analyses estimated a breakthrough bleeding incidence rate of 0.09 per year (95% confidence interval, 0.07-1.0). Although 58 people underwent a hysterectomy during the follow-up period, 64% of the cohort who maintained a uterus eventually experienced breakthrough bleeding. The median time to the initial bleeding episode was 22 months (interquartile range, 12-201) after testosterone initiation.CONCLUSION: These results suggest that a substantial fraction of transgender and gender-diverse individuals who are using testosterone will experience at least 1 episode of breakthrough bleeding even after their initial year of testosterone use. We recommend that clinicians inform all patients that breakthrough bleeding is a common occurrence even after the first year on testosterone therapy.

Endometrial Cancer in a Transgender Man with Prolonged Exogenous Testosterone Use

Endometrioid Endometrial Carcinoma With NKX3.1 Expression in a Transgender Man: A Case Report

Endometrial cancer and endometrial changes in transgender men: Insights from Japanese individuals on testosterone

Uterine changes in transgender men receiving testosterone therapy

Uterine and Ovarian Histopathology After Testosterone for Gender Affirmation: A Systematic Review

Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men

Breast and cervical cancer in transgender men: literature review and a case report

Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals

Incidental testicular germ cell tumor in a transgender woman: A case report

Prolactinoma in a Male to Female Transgender Woman on Gender Affirming Hormone Therapy

Hematospermia in a Transgender Woman with Evidence for Endometrial Tissue in the Prostate

Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival

Prevalence and Factors Associated With Prostate Cancer Among Transgender Women

An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism: A case report.

Scientific Evidence of Prostate Cancer Progression Outcomes in Transgender Females after Hormone Replacement Therapy-Scoping Review Protocol

Endocrine treatment of transgender individuals: current guidelines and strategies

Gender-affirming care and endocrine-related cancers

Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans

Incidence of breakthrough bleeding in transgender and gender-diverse individuals on long-term testosterone

(087) Testosterone Replacement Therapy in Men on Active Surveillance for Prostate Cancer: Using a Novel Database to Examine Disease Progression

Transgender patients and gender-affirming hormone therapy through the mid-life